Prolong Pharmaceuticals

Prolong Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated products that address unmet medical needs. The company is currently developing a portfolio of products in stroke, hematology, and oncology. Its lead asset, PP-007 (SANGUINATE™), addresses disorders involving ischemia, hypoxia, and/or hemolysis.